Differences

This shows you the differences between two versions of the page.

--- allison_mcgeer [2022/01/28 00:11]
liam [Sinai Health System]
+++ allison_mcgeer [2024/12/27 22:31] (current)
liam
@@ Line 28: / Line 28: @@
 ==== National Collaborating Centre for Infectious Diseases ====
-As of at least 2015, McGeer is listed as a Partner at the National Collaborating Centre for Infectious Diseases.((//Partners.// National Collaborating Centre for Infectious Diseases. Retrieved January 16, 2022, from https://archive.ph/CC1RX)) The centre is hosted at the [[University of Manitoba]], and receives funding from the [[public_health_agencies:canada:Public Health Agency of Canada]].
+As of at least 2015, McGeer is listed as a Partner at the [[National Collaborating Centre for Infectious Diseases]].((//Partners.// National Collaborating Centre for Infectious Diseases. Retrieved January 16, 2022, from https://archive.ph/CC1RX)) The centre is hosted at the [[University of Manitoba]], and receives funding from the [[public_health_agencies:canada:Public Health Agency of Canada]].
 ==== Ontario COVID-19 Science Advisory Table ====
@@ Line 54: / Line 54: @@
   * [[https://archive.ph/8T0hg|December 23, 2020]]: Influenza Vaccine Effectiveness Against All-Cause Mortality Following Laboratory-Confirmed Influenza in Older Adults, 2010-2011 to 2015-2016 Seasons in Ontario, Canada((Chung, H., Buchan, S. A., Campigotto, A., Campitelli, M. A., Crowcroft, N. S., Dubey, V., Gubbay, J. B., Karnauchow, T., Katz, K., McGeer, A. J., McNally, J. D., Mubareka, S., Murti, M., Richardson, D. C., Rosella, L. C., Schwartz, K. L., Smieja, M., Zahariadis, G., & Kwong, J. C. (2020). //Influenza Vaccine Effectiveness Against All-Cause Mortality Following Laboratory-Confirmed Influenza in Older Adults, 2010–2011 to 2015–2016 Seasons in Ontario, Canada.// Clinical Infectious Diseases, 73(5), e1191–e1199. https://doi.org/10.1093/cid/ciaa1862))
     * Funded by the [[Canadian Institutes of Health Research]] (CIHR) and [[public_health_agencies:canada:Public Health Ontario]].
-    * McGeer reported Conflicts of Interest due to receiving “grants and personal fees” from [[pharmaceutical_companies:Sanofi]] Pasteur and [[pharmaceutical_companies:Merck]]; personal fees from [[pharmaceutical_companies:GlaxoSmithKine]]; and grants from [[pharmaceutical_companies:Seqirus]].
+    * McGeer reported Conflicts of Interest due to receiving “grants and personal fees” from [[pharmaceutical_companies:Sanofi]] Pasteur and [[pharmaceutical_companies:Merck]]; personal fees from [[pharmaceutical_companies:GlaxoSmithKline]]; and grants from [[pharmaceutical_companies:Seqirus]].
   * [[https://archive.ph/Ca7Ug|August 27, 2021]]: //Neutralizing antibody responses to SARS-CoV-2 variants in vaccinated Ontario long-term care home residents and workers//((Abe, K. T., Hu, Q., Mozafarihashjin, M., Samson, R., Manguiat, K., Robinson, A., Rathod, B., Hardy, W. R., Wang, J. H., Iskilova, M., Pasculescu, A., Fazel-Zarandi, M., Li, A., Paterson, A., Chao, G., Green, K., Gilbert, L., Barati, S., Haq, N., . . . Gingras, A. C. (2021). //Neutralizing antibody responses to SARS-CoV-2 variants in vaccinated Ontario long-term care home residents and workers.// medRxiv. Published. https://doi.org/10.1101/2021.08.06.21261721)) ((Ireland, N. (2021, September 28). COVID-19 vaccine boosters recommended for long-term care residents, national advisory committee says. CBC News. Retrieved November 20, 2021, from https://archive.ph/NXtRs))
@@ Line 62: / Line 62: @@
     * McGeer disclosed that she received funding from [[pharmaceutical_companies:Pfizer]], [[pharmaceutical_companies:Merck]], [[pharmaceutical_companies:Medicago]], [[pharmaceutical_companies:Moderna]], [[pharmaceutical_companies:Janssen]], [[pharmaceutical_companies:GlaxoSmithKline]], and [[pharmaceutical_companies:AstraZeneca]].
+===== External links =====
+  * [[https://wiki.whiteroseintelligence.com/en/Allison-McGeer|White Rose Wiki]]
+{{tag>Pro-narrative_scientists}}